Výsledky vyhledávání - Luigi Gargiulo
- Zobrazuji výsledky 1 - 20 z 28
- Přejít na další stránku
-
1
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study Autor Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Jessica Avagliano, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Vydáno 2023Artigo -
2
-
3
-
4
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience Autor Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, Paola Facheris, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Vydáno 2023Artigo -
5
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review Autor Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Vydáno 2024Revisão -
6
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study Autor Luciano Ibba, S. Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti
Vydáno 2024Artigo -
7
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study Autor Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, A. Alfano, Ruggero Cascio Ingurgio, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Vydáno 2023Carta -
8
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab Autor Giulia Pavia, Luigi Gargiulo, Francesca Romana Spinelli, Jessica Avagliano, Mario Valenti, Riccardo G. Borroni, Antonio Costanzo, Alessandra Narcisi
Vydáno 2022Carta -
9
Impact of delay in follow‐up due to COVID‐19 pandemic on skin cancer progression: a real‐life experience from an Italian hub hospital Autor Mario Valenti, Giulia Pavia, Luigi Gargiulo, Paola Facheris, Ombretta Nucca, Luca Mancini, Francesco Sacrini, Riccardo G. Borroni, Alessandra Narcisi, Antonio Costanzo
Vydáno 2021Artigo -
10
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study Autor Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Carlo Alberto Vignoli, Francesco Piscazzi, Mario Valenti, Federica Sanna, Chiara Perugini, Jessica Avagliano, Antonio Costanzo, Alessandra Narcisi
Vydáno 2022Artigo -
11
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study Autor Luigi Gargiulo, Luciano Ibba, Matteo Bianco, S. Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Vydáno 2024Artigo -
12
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers Autor Diego Orsini, Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Mario Valenti, Chiara Perugini, Alessia Pacifico, Fabio Stefano Maramao, Pasquale Frascione, Antonio Costanzo, Alessandra Narcisi
Vydáno 2023Artigo -
13
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study... Autor Mario Valenti, Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Francesco Toso, Diego Orsini, Viviana Lora, Pasquale Frascione, Paolo Sena, Andrea Carugno, Chiara Assorgi, Antonio Costanzo, Alessandra Narcisi
Vydáno 2024Artigo -
14
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study Autor Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo
Vydáno 2021Artigo -
15
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus Autor Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, A. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia Mariel Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Mariateresa Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi
Vydáno 2024Artigo -
16
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review Autor M.A. Bianco, F D’Oria, Costanza Falcidia, Giulio Foggi, Elena Matteodo, S. Di Giulio, Paola Facheris, Luciano Ibba, Chiara Perugini, Mario Valenti, Carlo Alberto Vignoli, Antonio Costanzo, Alessandra Narcisi, Luigi Gargiulo
Vydáno 2025Revisão -
17
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—<scp>IL PSO</scp> (<scp>Italian landscape psoriasis</scp>) Autor Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Francesca Sampogna, Massimo Travaglini, Piergiorgio Malagoli, Antonio Costanzo
Vydáno 2022Artigo -
18
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) Autor Mario Valenti, Luciano Ibba, S. Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo Giovanni Carrera, Paolo Dapavo, Eugenia Veronica Di Brizzi, Valentina Dini, Francesca Maria Gaiani, Francesco Loconsole, Angelo Valerio Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi
Vydáno 2025Artigo -
19
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO... Autor Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Matteo Megna, Santo Raffaele Mercuri, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Vydáno 2024Artigo -
20
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – <scp>IL PSO... Autor Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo Giovanni Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofrè, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Mark S. Talamonti, Antonio Costanzo, Alessandra Narcisi
Vydáno 2023Artigo
Vyhledávací nástroje:
Související témata
Dermatology
Medicine
Internal medicine
Psoriasis
Retrospective cohort study
Atopic dermatitis
Psoriasis Area and Severity Index
Plaque psoriasis
Adverse effect
Clinical trial
Randomized controlled trial
Disease
Multicenter study
Pharmacology
Body mass index
Cytokine
Discontinuation
Gastroenterology
Intensive care medicine
Nursing
Physics
Quality of life (healthcare)
Severity of illness
Single Center
Surgery
Antibody
Center (category theory)
Chemistry
Computer science
Coronavirus disease 2019 (COVID-19)